Kura Oncology KURA
NASDAQ KURA
$7.57 -0.16 (-2.13%)
As of: Nov 12, 2026 · 1:02 PM EST

Kura Oncology (KURA) Return on Sales [ROS] (2025 - 2026)

Updated

Kura Oncology (KURA) reported Return on Sales [ROS] of -349.77% for Q2 2026, up 125.55 percentage points from -475.31% a year earlier and up 81.74 percentage points from the prior quarter.

Analysis

Kura Oncology (KURA) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Kura Oncology's Return on Sales [ROS] came in at -396.41%; for FY2025, it came in at -449.94%, down 91.40 percentage points from FY2024.

  • By year, Return on Sales [ROS] came in at -358.55% in FY2024.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -431.51% (Q1 2026), -464.82% (Q4 2025) and -355.29% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Kura Oncology 695.52 Mn -1.56 Bn 22.47 Mn -326.89%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -326.89%
Jun 30, 2026 -349.77%
Mar 31, 2026 -431.51%
Dec 31, 2025 -497.62%
Sep 30, 2025 -385.53%
Jun 30, 2025 -475.31%
Mar 31, 2025 -458.61%
API Access

Kura Oncology Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=KURA&period=max&api_key=YOUR_API_KEY